Tag
Big progress against two of the most deadly cancers reported from randomized trials, as highlighted by Eric Topol during the ASCO conference.
Daraxonrasib received a standing ovation at ASCO as Revolution Medicines' breakthrough against pancreatic cancer, celebrated by over 40,000 oncologists, entrepreneurs, investors, and patient advocates.